ArticleOpen forum infectious diseases2026
Respiratory Virus Coinfection Is a Risk Factor for Adverse Outcomes During
Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: We aimed to determine the impact of respiratory virus coinfection on clinical characteristics and outcomes of Methods: We conducted an analysis within a retrospective observational cohort study of consecutive adults with monomicrobial SAB between 08/01/2021 and 29/12/2024 in Southeast Scotland. Variables were compared between patients tested/not tested for respiratory viruses, then between patients with/without coinfection detected. Survival was compared using Kaplan-Meier curves. Multiple logistic regression was used to identify independent risk factors for mortality. Results: We identified 651 patients with SAB during the study period; 64.5% (420/651) underwent polymerase chain reaction testing for respiratory viruses, 9.1% of whom (38/420) tested positive (severe acute respiratory syndrome coronavirus 2, n = 30; influenza A, n = 7; respiratory syncytial virus, n = 1). There were no differences in baseline characteristics between those testing positive vs negative for respiratory virus coinfection, including age, sex, Charlson Comorbidity Index, and quick Sequential Organ Failure Assessment score. Presence of coinfection was associated with a respiratory portal of entry of SAB, that is, bacteremic pneumonia (21.1% with coinfection vs 5.2% without coinfection; Conclusions: Respiratory virus coinfection is a risk factor for bacteremic
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.